|
gptkbp:instanceOf
|
gptkb:drug
immunotherapy
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
1996
|
|
gptkbp:ATCCode
|
L03AB07
|
|
gptkbp:brand
|
gptkb:Rebif
gptkb:Avonex
|
|
gptkbp:CASNumber
|
189832-46-0
|
|
gptkbp:category
|
gptkb:insulin
cytokine
disease-modifying therapy
|
|
gptkbp:contraindication
|
hypersensitivity to interferon beta
|
|
gptkbp:discoveredBy
|
gptkb:Biogen
|
|
gptkbp:eliminatedIn
|
renal
hepatic
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:halfLife
|
10 hours (IM)
19 hours (SC)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
interferon beta-1a
|
|
gptkbp:immunogenicity
|
may induce neutralizing antibodies
|
|
gptkbp:indication
|
relapsing-remitting multiple sclerosis
clinically isolated syndrome
|
|
gptkbp:KEGGID
|
D04572
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Biogen
gptkb:Merck_Serono
|
|
gptkbp:mechanismOfAction
|
reduces inflammation
modulates immune response
|
|
gptkbp:molecularWeight
|
22.5 kDa
|
|
gptkbp:notRecommendedFor
|
gptkb:secondary_progressive_multiple_sclerosis
primary progressive multiple sclerosis
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionRequired
|
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103628s5222lbl.pdf
|
|
gptkbp:producedBy
|
gptkb:Chinese_hamster_ovary_cells
|
|
gptkbp:product
|
gptkb:protein
|
|
gptkbp:PubChem_CID
|
16129697
DB00060
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:depression
injection site reactions
flu-like symptoms
liver enzyme elevation
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:target
|
gptkb:interferon_receptors
|
|
gptkbp:UNII
|
P18A0J2Y9T
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Rebif
gptkb:Avonex
gptkb:Solidarity_trial_(WHO)
|
|
gptkbp:bfsLayer
|
6
|